AstraZeneca ships Flumist for 2018-2019 flu season
AstraZeneca on Wednesday announced the first shipment of Flumist Quadrivalent (Influenza Vaccine Live, Intranasal) doses in the United States for the 2018-2019 influenza season.
Flumist Quadrivalent, or the live attenuated influenza vaccine (LAIV), is sprayed into the nose to help protect against influenza. It can be used in children, adolescents and adults age 2 years old to 49 years old. Flumist Quadrivalent may not prevent influenza in everyone who gets vaccinated, the company said.
“Flumist Quadrivalent is the only CDC recommended needle-free, nasal spray flu vaccine, and has been approved in the United States since 2012,” AstraZeneca vice president U.S. respiratory Tosh Butt said.“AstraZeneca believes vaccination is the best way to protect against the flu and recognizes the importance of vaccine options to both patients and providers. Today, we are excited to begin shipping Flumist Quadrivalent for the 2018-2019 flu season.”
Earlier this year, the Advisory Committee on Immunization Practices, or ACIP, of the Centers for Disease Control and Prevention reinstated the recommendation for the use of Flumist Quadrivalent/LAIV as an option for flu vaccination in the United States for the 2018-2019 flu season. The recommendation states that there is no preference for one flu vaccine product over another, including Flumist Quadrivalent/LAIV, inactivated influenza vaccine and recombinant influenza vaccine. This was published in the Morbidity and Mortality Weekly Report, or MMWR, in June 2018, according to the company.
Flumist Quadrivalent, or the live attenuated influenza vaccine (LAIV), is sprayed into the nose to help protect against influenza. It can be used in children, adolescents and adults age 2 years old to 49 years old. Flumist Quadrivalent may not prevent influenza in everyone who gets vaccinated, the company said.
“Flumist Quadrivalent is the only CDC recommended needle-free, nasal spray flu vaccine, and has been approved in the United States since 2012,” AstraZeneca vice president U.S. respiratory Tosh Butt said.“AstraZeneca believes vaccination is the best way to protect against the flu and recognizes the importance of vaccine options to both patients and providers. Today, we are excited to begin shipping Flumist Quadrivalent for the 2018-2019 flu season.”
Earlier this year, the Advisory Committee on Immunization Practices, or ACIP, of the Centers for Disease Control and Prevention reinstated the recommendation for the use of Flumist Quadrivalent/LAIV as an option for flu vaccination in the United States for the 2018-2019 flu season. The recommendation states that there is no preference for one flu vaccine product over another, including Flumist Quadrivalent/LAIV, inactivated influenza vaccine and recombinant influenza vaccine. This was published in the Morbidity and Mortality Weekly Report, or MMWR, in June 2018, according to the company.